POINT Biopharma Global Inc

POINT Biopharma Global — Investor Presentation (February 2022)

47 slides from POINT Biopharma Global's investor presentation, Feb 25, 2022

  1. Slide 1: Accelerating Precision Medicine Investor Presentation

    Slide 1: Accelerating Precision Medicine Investor Presentation

    Accelerating Precision MedicineTM 1 February 2022 Investor Presentation NASDAQ: PNT Accelerating Precision Medicine™

  2. Slide 2: Legal Disclaimer

    Slide 2: Legal Disclaimer

    Accelerating Precision MedicineTM Legal Disclaimer 2 Except as otherwise indicated or unless the context otherwise requires, all references in this presentation to “we,” “our,” “us,” “POINT,” or the “Company” refer to POINT Biopharma Global Inc. This information contained in this presentation does n

  3. Slide 3: POINT Biopharma: Creating the platform for next-generation radiopharmaceuticals

    Slide 3: POINT Biopharma: Creating the platform for next-generation radiopharmaceuticals

    Accelerating Precision MedicineTM POINT Biopharma: Creating the platform for next-generation radiopharmaceuticals 3 POINT’S MISSION Accelerating the discovery, development and global access to life-changing radiopharmaceuticals POINT’S VISION Transforming lives touched by cancer INDUSTRY-LEADING PIP

  4. Slide 4: Radiopharmaceuticals will be a new pillar of oncology treatment

    Slide 4: Radiopharmaceuticals will be a new pillar of oncology treatment

    Accelerating Precision MedicineTM Radiopharmaceuticals will be a new pillar of oncology treatment with pan-cancer opportunities 4 MOLECULARLY TARGETED RADIATION Radiotherapy is a proven pillar of cancer treatment but lacks precision. By precisely delivering radiation directly to cancer cells with ra

  5. Slide 5: One of the most experienced radiopharmaceutical development and manufacturing teams

    Slide 5: One of the most experienced radiopharmaceutical development and manufacturing teams

    Accelerating Precision MedicineTM POINT has assembled one of the most experienced teams in the clinical development and manufacturing of radiopharmaceuticals 5 + 40+ CLINICAL TRIALS 30+ INDS, 30+ CTAS, 10+ INTERNATIONAL TRIALS + 12 APPROVALS 10 NDA/NDSS, 5 ANDA, 1 SNDS, 2 DMFS + 8 GMP RADIOPHARMACEU

  6. Slide 6: Novel ligands are expanding the cancer indications treatable with radiopharmaceuticals

    Slide 6: Novel ligands are expanding the cancer indications treatable with radiopharmaceuticals

    Accelerating Precision MedicineTM Novel ligands are greatly expanding the number of cancer indications that can be treated with radiopharmaceuticals 1. Baum et al. J Nucl Med 2016 6 Radioligands enable the precise targeting of cancer by combining a radioisotope, a linker & a targeting moiety that se

  7. Slide 7: New radioisotopes are further enhancing radiopharmaceuticals' capabilities

    Slide 7: New radioisotopes are further enhancing radiopharmaceuticals' capabilities

    Accelerating Precision MedicineTM New radioisotopes are further enhancing radiopharmaceuticals’ capabilities 7 POINT leverages the unique properties of a variety of medical isotopes. Isotope selection considerations include radiation type, energy emission, and half-life. Many modern radioisotopes ca

  8. Slide 8: Broad opportunity for combination therapies

    Slide 8: Broad opportunity for combination therapies

    Accelerating Precision MedicineTM Radiopharmaceuticals offer an extremely broad potential opportunity for combination therapies 8 Monotherapy and expected synergistic MoA with existing therapeutic classes MonotherapyActivation of anti-tumor immunity Sensitization to DNA Damage Response Inhibitors (D

  9. Slide 9: Platform overcomes barriers to radiopharmaceutical commercialization

    Slide 9: Platform overcomes barriers to radiopharmaceutical commercialization

    Accelerating Precision MedicineTM POINT’s platform overcomes the barriers that have prevented radiopharmaceutical commercialization 9 ManufacturingLate-Stage Programs There are currently no large-scale contract radiopharmaceutical manufacturing facilities Only three therapeutic radioligands currentl

  10. Slide 10: Manufacturing and supply chain are key success factors

    Slide 10: Manufacturing and supply chain are key success factors

    Accelerating Precision MedicineTM Manufacturing and supply chain are the key success factors: radiopharmaceuticals are made just- in-time with a useable life measured in days 10 POINT’s 100% owned & operated Indianapolis, Indiana manufacturing facility is currently supplying doses for the company’s

  11. Slide 11: Lutetium-177 and actinium-225 supply chains are industry-leading

    Slide 11: Lutetium-177 and actinium-225 supply chains are industry-leading

    Accelerating Precision MedicineTM POINT’s Facility 11 POINT’s lutetium-177 and actinium-225 supply chains are industry-leading Internal 177Lu production capability will provide a COGS advantage and supply chain redundancy Redundant 225Ac supply from partners with access to rare Thorium and Radium in

  12. Slide 12: POINT is positioned to be a leader in next-generation radiopharmaceuticals

    Slide 12: POINT is positioned to be a leader in next-generation radiopharmaceuticals

    Accelerating Precision MedicineTM POINT is positioned to be a leader in next-generation radiopharmaceuticals 12 Program Target Clinical Candidate Discovery Preclinical Phase 1 Phase 2 Phase 3 PSMA 177Lu-PSMA I&T PSMA 177Lu-PSMA I&T SSTR 177Lu-DOTA-TATE FAP-α 177Lu-PNT6555 FAP-α 225Ac-PNT6555 PSMA 22

  13. Slide 13: CanSEEK technology designed to improve precision and safety of radioligands

    Slide 13: CanSEEK technology designed to improve precision and safety of radioligands

    Accelerating Precision MedicineTM POINT is creating the future of radiopharmaceuticals with technologies like CanSEEK™, designed to improve the precision and safety of all radioligands Images are renderings, created for explanatory purposes only. The CanSEEKTM technology has been sub-licensed from b

  14. Slide 14: Anticipated Milestones & Financial Summary

    Slide 14: Anticipated Milestones & Financial Summary

    Accelerating Precision MedicineTM Anticipated Milestones & Financial Summary 14 Balance Sheet $252.8M cash & cash equivalents, as of Sept 30, 2021 Projected Runway Cash to fund operations into the first quarter of 2024 Capital Structure 90.1M Common Shares + 3.6M Options Program Clinical Candidate I

  15. Slide 15: Programs: 177Lu-PNT2002 PSMA-Targeted Ligand for mCRPC

    Slide 15: Programs: 177Lu-PNT2002 PSMA-Targeted Ligand for mCRPC

    Accelerating Precision MedicineTM Programs: 177Lu-PNT2002 PSMA-Targeted Ligand for mCRPC Top Line Data: Mid-2023

  16. Slide 16: PNT2002 is a PSMA-targeted therapy for mCRPC

    Slide 16: PNT2002 is a PSMA-targeted therapy for mCRPC

    Accelerating Precision MedicineTM PNT2002 is a PSMA-targeted therapy for metastatic Castration-Resistant Prostate Cancer (mCRPC), in an indication with >36,000 post-ARAT pre-chemo patients annually in the US 1. Beauregard et al. SNMMI Mid-Winter Meeting Feb 2022 2. US Patent 11,129,912 Sep 28 2021 1

  17. Slide 17: PSMA is a clinically-validated therapeutic target

    Slide 17: PSMA is a clinically-validated therapeutic target

    Accelerating Precision MedicineTM Prostate Specific Membrane Antigen (PSMA) is a clinically-validated therapeutic target, ideal for prostate cancer therapy 1. Hupe MC. et al. 2018. Front. Onc. 2. Pangalos MN. et al. 1999. J. Biol. Chem. 3. Davis M. et al. 2005. PNAS 4. Murphy GP. et al. 2000. Prosta

  18. Slide 18: PNT2002's Phase 3 Study for mCRPC: The SPLASH Protocol

    Slide 18: PNT2002's Phase 3 Study for mCRPC: The SPLASH Protocol

    Accelerating Precision MedicineTM PNT2002’s Phase 3 Study for mCRPC: The SPLASH Protocol 1. De Bono et al. N Engl J Med 2020; 382:2091-2102 2. Sweeney et al. AACR 2020 18 Study Evaluating Metastatic Castrate Resistant Prostate Cancer Using 177Lu-PNT2002 PSMA Therapy versus Abiraterone or Enzalutamid

  19. Slide 19: Cumulative Administered Activity SPLASH Trial Lead-In

    Slide 19: Cumulative Administered Activity SPLASH Trial Lead-In

    Accelerating Precision MedicineTM 19 Cumulative Administered Activity SPLASH Trial Lead-In1 (N=27) Median Dose 6.8 GBq / 4 cycles Total Kidneys 19.9 Gy Total Red Marrow 0.91 Gy Total Lacrimal Gland 33.7 Gy Total Salivary Gland 9.15 Gy PNT2002 (PSMA-I&T) Baum2 Median Dose 5.8 (3.6-8.7) GBq / 2 (1-5)

  20. Slide 20: Four DSMB meetings completed with no recommended changes

    Slide 20: Four DSMB meetings completed with no recommended changes

    Accelerating Precision MedicineTM 20 Four DSMB meetings completed to date with no recommended changes to study conduct or protocol FDA agreement to proceed with randomization ahead of schedule in December 2021 Red marrow dosimetry well below critical thresholds enabling the potential opportunity for

  21. Slide 21: Randomization has begun in US and Canada

    Slide 21: Randomization has begun in US and Canada

    Accelerating Precision MedicineTM Randomization has begun in US and Canada, ongoing EU expansion to expedite accrual 21 Initiate EU Expansion Q4 2021 Start of US Randomization December 2021 Present Dosimetry Data at SNMMI February 2022 NDA Planning and Continued FDA Engagements Q2 2022 – Q3 2023 Top

  22. Slide 22: Programs: 177Lu-PNT2003 SSTR Targeting Ligand for Neuroendocrine Cancer

    Slide 22: Programs: 177Lu-PNT2003 SSTR Targeting Ligand for Neuroendocrine Cancer

    Accelerating Precision MedicineTM Programs: 177Lu-PNT2003 SSTR Targeting Ligand for Neuroendocrine Cancer

  23. Slide 23: PNT2003 is a somatostatin receptor targeted treatment for NETs

    Slide 23: PNT2003 is a somatostatin receptor targeted treatment for NETs

    Accelerating Precision MedicineTM PNT2003 is a somatostatin receptor targeted treatment for Neuroendocrine cancer (NETs) 1. Oronsky B. et al. 2017, 2. Dasari A. et al. 2017. 23 NETs are heterogeneous tumors that originate in neuroendocrine cells1. • PNT2003 uses the SSTR-targeted DOTA- TATE ligand,

  24. Slide 24: Somatostatin receptors are a validated target for NETs therapy

    Slide 24: Somatostatin receptors are a validated target for NETs therapy

    Accelerating Precision MedicineTM Somatostatin receptors (SSTRs) are a validated target for NETs therapy 1. Caplin ME. et al. 2014. NEJM 2. Rinke et al. 2009. JCO. 3. Patel YC. et al. 1997. Endocrin. Metabo. 4. Yang SK. et al. 2007. Clin. Exp. Pharm. Phys. 5. Papotti M. et al. 2002. Virch. Arch. 24

  25. Slide 25: PNT2003's reduced radiation safety burden offers differentiation

    Slide 25: PNT2003's reduced radiation safety burden offers differentiation

    Accelerating Precision MedicineTM PNT2003’s reduced radiation safety burden offers a significant opportunity for differentiation from the currently approved radiopharmaceutical product for the GEP-NETs indication 25 The 177Lu in PNT2003 does not contain long-lived radioactive impurities, resulting i

  26. Slide 26: NETs is a large market opportunity with multiple regulatory pathways

    Slide 26: NETs is a large market opportunity with multiple regulatory pathways

    Accelerating Precision MedicineTM Neuroendocrine Tumors (NETs) is a large market opportunity; there are multiple potential regulatory pathways available to PNT2003 (DOTA-TATE) 1. Oronsky B. et al. 2017. Neoplasia 2. NETs – SEER 18 3. Dasari A. et al. 2017. JAMA 4. Man D. et al. 2018 26 POINT is curr

  27. Slide 27: Next Generation: Novel Targets, Improved Ligands, and Transformational Technologies

    Slide 27: Next Generation: Novel Targets, Improved Ligands, and Transformational Technologies

    Accelerating Precision MedicineTM Next Generation: Novel Targets, Improved Ligands, and Transformational Technologies

  28. Slide 28: The next generation of radiopharmaceuticals

    Slide 28: The next generation of radiopharmaceuticals

    Accelerating Precision MedicineTM The next generation of radiopharmaceuticals will require novel targets, improved ligands, and transformation technologies 28 Novel Targets Improved Ligands Transformational Technologies Pan-cancer approaches Better patient outcomes Enhanced therapeutic windows PNT20

  29. Slide 29: Programs: PNT2004 Fibroblast Activation Protein-α Targeting Ligand

    Slide 29: Programs: PNT2004 Fibroblast Activation Protein-α Targeting Ligand

    Accelerating Precision MedicineTM Programs: PNT2004 Fibroblast Activation Protein-α Targeting Ligand for Multiple Tumor Types

  30. Slide 30: PNT2004 is a best-in-class FAP-α targeted radioligand

    Slide 30: PNT2004 is a best-in-class FAP-α targeted radioligand

    Accelerating Precision MedicineTM PNT2004 is a best-in-class Fibroblast Activation Protein (FAP-α) targeted radioligand with potential for imaging and therapy 30 An ideal radiopharmaceutical targets and is retained in tumors, while flushing out of tissues absent of the target quickly. Developed in c

  31. Slide 31: FAP-α is a pan cancer target found in >90% of epithelial tumors

    Slide 31: FAP-α is a pan cancer target found in >90% of epithelial tumors

    Accelerating Precision MedicineTM FAP-α is a compelling pan cancer target for imaging and therapy that is found in >90% of epithelial tumors1 1. Mhawech-Fauceglia P. et al. 2015. Canc. Microenv. 2. Jacob M. et al. 2012. Curr. Mol. Med. 3. Mariathasan S, et al. 2018. Nature 4. Domen A. et al. 2021. C

  32. Slide 32: 68Ga-PNT6555 biodistribution shows fast tumor targeting

    Slide 32: 68Ga-PNT6555 biodistribution shows fast tumor targeting

    Accelerating Precision MedicineTM PNT6555 is the lead of the PNT2004 program. 68Ga-PNT6555 biodistribution studies demonstrate fast tumor targeting with little accumulation in normal tissues 32 Rapid renal clearance of excess compound and good tumor retention with low background in other organs. 68G

  33. Slide 33: 177Lu-PNT6555 biodistribution shows prolonged tumor retention

    Slide 33: 177Lu-PNT6555 biodistribution shows prolonged tumor retention

    Accelerating Precision MedicineTM 177Lu-PNT6555 biodistribution studies demonstrate prolonged tumor retention and rapid normal tissue clearance 33 Rapid and persistent tumor targeting beyond 7 days with low retention in normal tissues, with exquisite tumor / kidney ratio. Organ uptake 177Lu-PNT6555

  34. Slide 34: 177Lu-PNT6555 shows anti-tumor activity with long-term survival

    Slide 34: 177Lu-PNT6555 shows anti-tumor activity with long-term survival

    Accelerating Precision MedicineTM 177Lu-PNT6555 shows compelling anti-tumor activity, with mice experiencing long-term survival 34 Tumor Volumes on Day 22Tumor Volumes Kaplan-Meier Survival Curves HEK-mFAP model, n=6/group, single dose treatment in mice with tumors (~200mm 3), ns=not significant, *p

  35. Slide 35: PNT2004 is on track for a CTA Submission in Q1 2022

    Slide 35: PNT2004 is on track for a CTA Submission in Q1 2022

    Accelerating Precision MedicineTM PNT2004 is on track for a CTA Submission in Q1 2022 35 Lead selected. IND-enabling efficacy, biodistribution and toxicology studies complete. Additional studies in syngeneic and PDX models underway. Process and method optimization and validation with target complete

  36. Slide 36: Programs: PNT2001 Next-Generation PSMA Targeting Ligand

    Slide 36: Programs: PNT2001 Next-Generation PSMA Targeting Ligand

    Accelerating Precision MedicineTM Programs: PNT2001 Next-Generation PSMA Targeting Ligand

  37. Slide 37: PNT2001 is a next-generation PSMA radioligand

    Slide 37: PNT2001 is a next-generation PSMA radioligand

    Accelerating Precision MedicineTM PNT2001 is a next-generation PSMA radioligand optimized for earlier treatment & delivery of 225Ac 37 1. NPCR and SEER 2005-2016 Registries 2. Scher et al. PLOS ONE, 2015 3. Borofsky et al. Radiology, 2017 4. POINT Primary Market Research, Dec 2020 5. Thoma et al. Na

  38. Slide 38: PNT2001 linker technology increases internalization and tumor uptake

    Slide 38: PNT2001 linker technology increases internalization and tumor uptake

    Accelerating Precision MedicineTM PNT2001 has linker technology that allows for increased internalization into cells, resulting in increased tumor uptake Unpublished data 38 This profile could result in the same outcomes seen with today’s technology at a lower dose, potentially allowing for a reduct

  39. Slide 39: 225Ac-PNT2001 shows efficacy in pre-clinical tumor models

    Slide 39: 225Ac-PNT2001 shows efficacy in pre-clinical tumor models

    Accelerating Precision MedicineTM Unpublished data LNCaP model, n=6/group, single dose treatment in mice with large tumors (~600mm 3), ns=not significant, *p<0.05, **p<0.01, ***p<0.001, **** p<0.0001 39 Next step: IND-enabling studies in 2022 225Ac-PNT2001 shows compelling efficacy as a single dose

  40. Slide 40: Programs: CanSEEK FAP-α Activated Prodrug Technology Platform

    Slide 40: Programs: CanSEEK FAP-α Activated Prodrug Technology Platform

    Accelerating Precision MedicineTM Programs: CanSEEK™ FAP-α Activated Prodrug Technology Platform

  41. Slide 41: Off-target delivery is limiting usage of next-generation radioisotopes

    Slide 41: Off-target delivery is limiting usage of next-generation radioisotopes

    Accelerating Precision MedicineTM Early 225Ac clinical data demonstrates the off-target delivery is limiting usage of next-generation radioisotopes 41 1. Kratochwil, C, et al. J Nucl Med 2016 2. Zacherl, M, et al. J Nucl Med 2020 3. Ruigrok, E, et al. Pharmaceceutics 2019 3 cycles of 9-10 MBq 225Ac-

  42. Slide 42: CanSEEK prodrug platform improves precision, efficacy and safety

    Slide 42: CanSEEK prodrug platform improves precision, efficacy and safety

    Accelerating Precision MedicineTM The goal of the CanSEEK™ prodrug technology platform is to improve precision, efficacy and safety of all radioligands 1. Mhawech-Fauceglia P. et al. 2015. Canc. Microenv. 42 • CanSEEK™, currently in pre-clinical development, prevents a radioligand from binding to re

  43. Slide 43: CanSEEK enables re-evaluation of known ligands

    Slide 43: CanSEEK enables re-evaluation of known ligands

    Accelerating Precision MedicineTM CanSEEK™ is as a radiopharmaceutical drug platform that enables re-evaluation of known ligands previously set aside due to off-target delivery concerns 43 • By extending the therapeutic index of ligands, CanSEEK™ could also enable the use of emerging medical isotope

  44. Slide 44: Summary & Milestones

    Slide 44: Summary & Milestones

    Accelerating Precision MedicineTM Summary & Milestones

  45. Slide 45: POINT will drive innovation in radiopharmaceuticals

    Slide 45: POINT will drive innovation in radiopharmaceuticals

    Accelerating Precision MedicineTM POINT will drive innovation in radiopharmaceuticals by overcoming their current limitations 45 THE FUTURE OF RADIOPHARMACEUTICALS CanSEEK™ prodrug technology in development to increase efficacy and safety Partnering with sources of emerging alpha, beta and auger emi

  46. Slide 46: Anticipated Milestones & Financial Summary

    Slide 46: Anticipated Milestones & Financial Summary

    Accelerating Precision MedicineTM Anticipated Milestones & Financial Summary 46 Program Clinical Candidate Indication Timing (Est.) Milestone Completed Manufacturing 177Lu-PSMA I&T mCRPC Q4 2021 IND Amendment to add facility to supply chain 177Lu-PSMA I&T mCRPC Q1 2022 Dosimetry presentation from 27

  47. Slide 47: Contact

    Slide 47: Contact

    Accelerating Precision MedicineTM 47 NASDAQ: PNT Accelerating Precision Medicine™ investors@pointb iopharma.com POINTBiopharma.com

Source: SEC EDGAR · 8-K filed Feb 25, 2022

More decks from POINT Biopharma Global Inc